Lactimidomycin is a broad-spectrum inhibitor of dengue and other RNA viruses

Antiviral Research

Volumn 128, Issue , 2016, Pages 57-62

  Carocci, Margot ^a   Yang, Priscilla L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiviral; Broad spectrum; Dengue virus; Host targeted antiviral; Lactimidomycin; Translation inhibitor

Indexed keywords

ANTIVIRUS AGENT; CYCLOHEXIMIDE; LACTIMIDOMYCIN; MYCOPHENOLIC ACID; NATURAL PRODUCT; TRANSFER RNA; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA; MACROLIDE; PIPERIDONE DERIVATIVE;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; APOPTOSIS; ARTICLE; CC50; CELL CULTURE; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 2; DRUG BINDING; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG POTENCY; ELECTROPORATION; ENZYME ACTIVITY; FLAVIVIRUS; HUMAN; HUMAN CELL; HUMAN POLIOVIRUS 1; KUNJIN VIRUS; MODOC VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REPLICON; RNA TRANSLATION; RNA VIRUS; SINGLE-STRANDED RNA VIRUS; STEADY STATE; TRANSLATION INITIATION; VERO CELL LINE; VESICULOVIRUS; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; CELL LINE; CHLOROCEBUS AETHIOPS; DENGUE VIRUS; DRUG EFFECTS;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; DENGUE VIRUS; HUMANS; MACROLIDES; PEPTIDE CHAIN ELONGATION, TRANSLATIONAL; PIPERIDONES; RNA VIRUSES; VERO CELLS;

EID: 84959016756     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.02.005     Document Type: Article

References (35)

1. V.I. Agol, G.A. Belov, K. Bienz, D. Egger, M.S. Kolesnikova, L.I. Romanova, L.V. Sladkova, and E.A. Tolskaya Competing death programs in poliovirus-infected cells: commitment switch in the middle of the infectious cycle J. Virol. 74 2000 5534 5541
2. S. Bhatt, P.W. Gething, O.J. Brady, J.P. Messina, A.W. Farlow, C.L. Moyes, J.M. Drake, J.S. Brownstein, A.G. Hoen, O. Sankoh, M.F. Myers, D.B. George, T. Jaenisch, G.R. Wint, C.P. Simmons, T.W. Scott, J.J. Farrar, and S.I. Hay The global distribution and burden of dengue Nature 496 2013 504 507
3. M. Carocci, S.M. Hinshaw, M.A. Rodgers, V.A. Villareal, D.J. Burri, R. Pilankatta, N.P. Maharaj, M.U. Gack, E.J. Stavale, K.L. Warfield, and P.L. Yang The bioactive lipid 4-hydroxyphenyl retinamide inhibits flavivirus replication Antimicrob. Agents Chemother. 59 2015 85 95
4. K. Clyde, J. Barrera, and E. Harris The capsid-coding region hairpin element (cHP) is a critical determinant of dengue virus and West Nile virus RNA synthesis Virology 379 2008 314 323
5. D. Edgil, M.S. Diamond, K.L. Holden, S.M. Paranjape, and E. Harris Translation efficiency determines differences in cellular infection among dengue virus type 2 strains Virology 317 2003 275 290
6. P. Gadaleta, X. Perfetti, S. Mersich, and F. Coulombie Early activation of the mitochondrial apoptotic pathway in Vesicular Stomatitis virus-infected cells Virus Res. 109 2005 65 69
7. R.E. Gosselin, R.P. Smith, and H.C. Hodge Clinical Toxicology of Commercial Products fifth ed. 1984 Williams and Wilkins 428 East Preston Street, Baltimore, MD 21202 1987 + ix pp. 26 × 17.5 cm. ISBN 0-683-03632-7
8. M.G. Guzman, M. Alvarez, and S.B. Halstead Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection Arch. Virol. 158 2013 1445 1459
9. R.J. Jackson, C.U. Hellen, and T.V. Pestova The mechanism of eukaryotic translation initiation and principles of its regulation Nat. Rev. Mol. Cell Biol. 11 2010 113 127
10. J. Ju, S.K. Lim, H. Jiang, and B. Shen Migrastatin and dorrigocins are shunt metabolites of iso-migrastatin J. Am. Chem. Soc. 127 2005 1622 1623
11. B.J. Larsen, Z. Sun, E. Lachacz, Y. Khomutnyk, M.B. Soellner, and P. Nagorny Synthesis and biological evaluation of lactimidomycin and its analogues Chemistry 21 2015 19159 19167
12. A.S. Lee, R. Burdeinick-Kerr, and S.P. Whelan A ribosome-specialized translation initiation pathway is required for cap-dependent translation of vesicular stomatitis virus mRNAs Proc. Natl. Acad. Sci. U. S. A. 110 2013 324 329
13. I. Lepran, M. Koltai, and L. Szekeres Effect of actinomycin D and cycloheximide on experimental myocardial infarction in rats Eur. J. Pharmacol. 77 1982 197 199
14. R.J. Lewis Sax's Dangerous Properties of Industrial Materials ninth ed. 1996
15. C.L. Liang, L.C. Yang, K. Lu, H.C. Hsu, C.L. Cho, S.D. Chen, H.Y. Huang, and H.J. Chen Neuroprotective synergy of N-methyl-D-aspartate receptor antagonist (MK801) and protein synthesis inhibitor (cycloheximide) on spinal cord ischemia-reperfusion injury in rats J. Neurotrauma 20 2003 195 206
16. J.G. Low, C. Sung, L. Wijaya, Y. Wei, A.P. Rathore, S. Watanabe, B.H. Tan, L. Toh, L.T. Chua, Y. Hou, A. Chow, S. Howe, W.K. Chan, K.H. Tan, J.S. Chung, B.P. Cherng, D.C. Lye, P.A. Tambayah, L.C. Ng, J. Connolly, M.L. Hibberd, Y.S. Leo, Y.B. Cheung, E.E. Ooi, and S.G. Vasudevan Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial Lancet Infect. Dis. 14 2014 706 715
17. A. Lwoff The concept of virus J. Gen. Microbiol. 17 1957 239 253
18. K. Micoine, P. Persich, J. Llaveria, M.H. Lam, A. Maderna, F. Loganzo, and A. Furstner Total syntheses and biological reassessment of lactimidomycin, isomigrastatin and congener glutarimide antibiotics Chemistry 19 2013 7370 7383
19. B.R. Murphy, and S.S. Whitehead Immune response to dengue virus and prospects for a vaccine Annu. Rev. Immunol. 29 2011 587 619
20. S. Musat-Marcu, H.E. Gunter, B.I. Jugdutt, and J.C. Docherty Inhibition of apoptosis after ischemia-reperfusion in rat myocardium by cycloheximide J. Mol. Cell Cardiol. 31 1999 1073 1082
21. C.G. Noble, Y.L. Chen, H. Dong, F. Gu, S.P. Lim, W. Schul, Q.Y. Wang, and P.Y. Shi Strategies for development of Dengue virus inhibitors Antivir. Res. 85 2010 450 462
22. S.T. Perry, M.D. Buck, E.M. Plummer, R.A. Penmasta, H. Batra, E.J. Stavale, K.L. Warfield, R.A. Dwek, T.D. Butters, D.S. Alonzi, S.M. Lada, K. King, B. Klose, U. Ramstedt, and S. Shresta An iminosugar with potent inhibition of dengue virus infection in vivo Antivir. Res. 98 2013 35 43
23. E. Plummer, M.D. Buck, M. Sanchez, J.A. Greenbaum, J. Turner, R. Grewal, B. Klose, A. Sampath, K.L. Warfield, B. Peters, U. Ramstedt, and S. Shresta Dengue virus evolution under a host-targeted antiviral J. Virol. 89 2015 5592 5601
24. T.V. Ramabhadran, and R.E. Thach Specificity of protein synthesis inhibitors in the inhibition of encephalomyocarditis virus replication J. Virol. 34 1980 293 296
25. A.P. Rathore, P.N. Paradkar, S. Watanabe, K.H. Tan, C. Sung, J.E. Connolly, J. Low, E.E. Ooi, and S.G. Vasudevan Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model Antivir. Res. 92 2011 453 460
26. J.D. Richter, and J. Coller Pausing on Polyribosomes: make Way for elongation in translational control Cell 163 2015 292 300
27. T. Schneider-Poetsch, J. Ju, D.E. Eyler, Y. Dang, S. Bhat, W.C. Merrick, R. Green, B. Shen, and J.O. Liu Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin Nat. Chem. Biol. 6 2010 209 217
28. T. Schneider-Poetsch, T. Usui, D. Kaida, and M. Yoshida Garbled messages and corrupted translations Nat. Chem. Biol. 6 2010 189 198
29. K. Sugawara, Y. Nishiyama, S. Toda, N. Komiyama, M. Hatori, T. Moriyama, Y. Sawada, H. Kamei, M. Konishi, and T. Oki Lactimidomycin, a new glutarimide group antibiotic. Production, isolation, structure and biological activity J. Antibiot. (Tokyo) 45 1992 1433 1441
30. T.R. Sweeney, I.S. Abaeva, T.V. Pestova, and C.U. Hellen The mechanism of translation initiation on Type 1 picornavirus IRESs EMBO J. 33 2014 76 92
31. D. Walsh, M.B. Mathews, and I. Mohr Tinkering with translation: protein synthesis in virus-infected cells Cold Spring Harb. Perspect. Biol. 5 2013 a012351
32. S. Watanabe, K.W. Chan, G. Dow, E.E. Ooi, J.G. Low, and S.G. Vasudevan Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: the search for a window for potential therapeutic efficacy Antivir. Res. 127 2016 10 19
33. S. Watanabe, A.P. Rathore, C. Sung, F. Lu, Y.M. Khoo, J. Connolly, J. Low, E.E. Ooi, H.S. Lee, and S.G. Vasudevan Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial Antivir. Res. 96 2012 32 35
34. K. Whitby, T.C. Pierson, B. Geiss, K. Lane, M. Engle, Y. Zhou, R.W. Doms, and M.S. Diamond Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo J. Virol. 79 2005 8698 8706
35. P.M. Yau, T. Godefroy-Colburn, C.H. Birge, T.V. Ramabhadran, and R.E. Thach Specificity of interferon action in protein synthesis J. Virol. 27 1978 648 658